Please login to the form below
Canada
This page shows the latest Canada news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
AstraZeneca and MSD's – known as Merck &Co in the US and Canada – Lynparza (olaparib) has been approved in the UK as part of a combination therapy for certain prostate cancer
Latest news
-
Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
More than 60 countries have already approved this Polivy combination for the treatment of adult patients with previously untreated DLBCL, including in the EU, UK, Japan, Canada and China.
-
Merck reports positive results for Keytruda combination in malignant pleural mesothelioma
Merck &Co (Merck) – known as MSD outside the US and Canada – has reported positive results from a phase 2/3 study of its anti-PD-1 therapy Keytruda (pembrolizumab) in combination
-
AstraZeneca announces major expansion of Canadian research footprint
AstraZeneca (AZ) has announced a major expansion of its research footprint in Canada with the creation of 500 highly-skilled jobs and a new Alexion rare disease research hub. ... Kiersten Combs, president of AZ Canada, said: "We're pleased to see the
-
Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation
Moderna and Merck – known as MSD outside the US and Canada – have said their investigational personalised mRNA cancer vaccine, in combination with Merck’s Keytruda, has been given breakthrough therapy designation
-
Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households
Merck – known as MSD outside the US and Canada – has reported that its COVID-19 pill, jointly developed with Ridgeback, did not significantly reduce the risk of infections in those living
More from news
Approximately 11 fully matching, plus 790 partially matching documents found.
Latest Intelligence
-
Envisioning a healthier every day, for every woman
known as Merck &Co in the US and Canada) with a mission to create improved health outcomes for women around the world.
-
Lessons from a pandemic – holistic strategy in the time of coronavirus
the component countries are as diverse and complicated as India and the USA, or Canada and Cameroon.
-
Health technology assessments: understanding the global landscape and considerations for drug development
Outside Europe, countries like Australia, Canada and Japan have established HTAs.
-
Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
With over 12, 000 participants in key specialties across Europe, Latin America, Canada, Asia and MENA, the recent Global Physician Specialty Survey is Medscape’s latest and largest ever source of
-
A new era for UK-Japanese scientific research relations
The TPP covers 11 pacific trading nations, including Australia, New Zealand, Canada and Malaysia, valued at 13% of the global economy and more than £110bn of trade in 2019.
More from intelligence
Approximately 1 fully matching, plus 80 partially matching documents found.
Latest appointments
-
EFPIA appoints Hubertus von Baumbach as president
Baumbach had been a member of Boehringer’s board of managing directors since 2009, and he has also previously worked at Roche in the US and for Boehringer in Canada.
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health.
-
Syneos Health Communications announces senior hires to Europe-based team
Previously, he served as communications director for Lilly’s Europe, Australia and Canada operations.
-
McCann Health North America appoints Jim Joseph as president
Joseph will oversee all North American advertising and promotion agencies in the US and Canada. ... In his new role at McCann Health, he will oversee all North American advertising and promotion agencies in the US and Canada, and will build and expand
-
Ashfield, Health Unlimited and Ashley Communications add to their teams
Nigel Mansford, Regional President for Ashfield Clinical and Commercial Europe and Canada, said: “Pierre is a charismatic and people-focused leader who will bring drive, energy and innovation to the role. ... Van Weperen will be part of the Europe and
More from appointments
Approximately 1 fully matching, plus 62 partially matching documents found.
Latest from PMHub
-
The Evolving Role of Social Media in Healthcare
Ontario. M5J 2N8. Canada.
-
Streamlining Healthcare Delivery Through Digital Care Journeys
Ontario. M5J 2N8. Canada.
-
Insight Gathering for Life Science Companies
Ontario. M5J 2N8. Canada.
-
Applying Vibrotactile Stimulation to Improve Parkinson's
Ontario. M5J 2N8. Canada.
-
Impetus Digital's Virtual Learning Programs named PM360's Most Innovative Services of 2022
Ontario. M5J 2N8. Canada.
More from PMHub
Approximately 6 fully matching, plus 344 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
